Abstract:The development of inhibitory antibodies (inhibitors) is a critical issue in the replacement therapy of hemophilia. The effective therapy of hemophilia with inhibitors is still an urgent demand. In the coagulation cascade, factor X (FX) is the common point of both intrinsic and extrinsic pathway. FX is activated to factor Xa (FXa) by either factor IXa (FIXa)/factor VIIIa (FVIIIa) or factor VIIa (FVIIa)/tissue factor (TF) complexes. FXa forms a prothrombinase complex with factor Va (FVa), and activates prothrombin to thrombin. Since FXa activates prothrombin very efficiently and this process bypasses FIX and FVIII, it has been tried as a bypassing agent in the treatment of hemophilia with inhibitors for a long time. It was found that infusion of FXa in the plasma could alleviate the bleeding phenotype of hemophilia animals. However, studies disclosed that the half-life of FXa is too short to be an effective bypassing agent. Furthermore, improved plasma FXa concentration also increases the risk of disseminated intravascular coagulation (DIC). A protein ectopically expressed in platelets can be stored in platelets, and it can be released during the activation of platelets. Here, we hypothesize that if FXa can be targeted expressed and stored in platelets, the half-life of FXa could be increased, while at the same time the risk of DIC could be largely limited. When platelets are activated at the injury site, the stored FXa can be released and activate prothrombin on the surface of platelets, so as to initiate the blood coagulation. Thus, this platelet-stored FXa could be used in the treatment of hemophilia A (HA) and hemophilia B (HB) with inhibitors. To prove our hypothesis, we constructed a platelet-targeted FXa expression cassette (2bFXa) by putting FXa under the control of GPαIIb promoter. Then we made the corresponding lentiviral vector with this 2bFXa cassette. The 2bFXa lentiviral vector was used to transduce hematopoietic stem cells (HSCs) collected from HA and HB mice, the modified HSCs were then transplanted back into the lethally irradiated corresponding HA and HB recipient mice. We collected plasma and platelets from the recipients. FXa was successfully detected in the platelets but not in the plasma of both HA and HB recipients by either an FXa activity assay or FX ELISA. The level of platelet-stored FXa remains constant throughout the experiment. Platelet release assay indicates almost 85.7% stored FXa can be released after the stimulation of platelets. The storage of FXa in platelets was also demonstrated by confocal microscopy and flow cytometry analysis. We then carried out a tail clip survival test to evaluate the phenotypic correction of recipients, all HA and HB recipient mice survived the tail clip challenge, demonstrating the platelet-stored FXa is biologically functional. We also tested the same strategy on HA mice with inhibitors and acquired the same results, indicating that the strategy is effective for HA with inhibitors. During the whole period of experiment, the recipient mice were all in good health. We also kept on monitoring the complete blood cell counts for 48 weeks and the cell numbers remained in normal range, indicating that the blood cells were successfully recovered in the recipients. Taken together, our proof of principle studies suggest that targeting FXa expression in platelets could facilitate the storage of FXa in platelets and would not cause obvious FXa leakage. The platelet-stored FXa is active and can be released with the activation of platelets and corrects the bleeding phenotype of HA and HB mice. This new gene therapy method could eliminate the shortage of FXa and be functional in the treatment of hemophilia with inhibitors. Disclosures No relevant conflicts of interest to declare.

Stable Expression of Native Coagulation Factor VIII Using the 2A Self-Processing Sequence and Furin Cleavage Site.

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

857. Molecular Engineering of Factor VIII for Raav Delivery

Enhanced factor VIII heavy chain for gene therapy of hemophilia A.

Expression, Purification and Characterization of Recombinant Human Coagulation Factor XIIIa in Pichia Pastoris

Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based system

Bioengineering Hemophilia A-specific Microvascular Grafts for Delivery of Full-Length Factor VIII into the Bloodstream

Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy

Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.

The Enhancing Effects of the Light Chain on Heavy Chain Secretion in Split Delivery of Factor VIII Gene

Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain

Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies

Targeted genome engineering based on CRISPR/Cas9 system to enhance FVIII expression in vitro

Expression of Human Clotting Factor Ix Mediated by Recombinant Lentiviral Vector in Cultured Cells and Hemophilia B Mice

Targeting Factor Xa Expression in Platelets As a Potential Gene Therapy Strategy for Hemophilia with Inhibitors

Roles of Phytanoyl-CoA α-Hydroxylase in Mediating the Expression of Human Coagulation Factor VIII

An Essential Role of the Factor VIII Light Chain in Facilitating Heavy Chain Secretion.

Overcoming Hemophilia A Gene Therapy Limitations with an Enhanced Function Factor VIII Variant

Identification of the Efficient Enhancer Elements in FVIII-Padua for Gene Therapy Study of Hemophilia A

Gene Therapy for Hemophilia B Mediated by Recombinant Adeno-Associated Viral Vector with Hfixr338a,a High Catalytic Activity Mutation of Human Coagulation Factor IX

Activated factor X delivered by adeno-associated virus significantly inhibited bleeding and alleviated hemophilic synovitis in hemophilic mice